Yes. Robotic hysterectomy consistently demonstrates lower blood loss, fewer post-operative complications, shorter hospital stay (1–2 days vs. 5–7 days for open surgery), and equivalent cancer outcomes. The magnified 3D view reduces the risk of inadvertent injury to surrounding structures such as the ureter and bladder.

Yes, robotic myomectomy is specifically designed to preserve the uterus and fertility. The superior suturing capability of the Da Vinci Xi allows for layered uterine closure that reduces adhesion formation and supports a healthy subsequent pregnancy.

Most patients are discharged within 24–48 hours and return to desk work within 1–2 weeks. Full recovery to normal activities is usually within 2–4 weeks, compared to 6–8 weeks for open surgery.

Both are mesh-augmented robotic procedures for pelvic organ prolapse, but they use different anatomical fixation points. Sacrocolpopexy anchors the vaginal vault to the sacrum, while Pectopexy anchors it to the iliopectineal ligament. Pectopexy avoids the presacral space and may have a lower risk of certain complications. Both are effective options depending on individual anatomy.

Robotic surgery may be considered for women requiring hysterectomy, myomectomy, endometriosis surgery, pelvic reconstructive surgery, selected urogynecological procedures or certain gynaecological cancer surgeries. Suitability is determined after consultation, physical examination, imaging and review of the patient's medical and surgical history.